Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) EPS (diluted)
Zoetis Inc.'s EPS (diluted) for fiscal 2025 was $6.02, up 10.1% from $5.47 in fiscal 2024. Over the twelve months to 30 June 2026 it was $6.07. Over the past ten years it has ranged from $0.68 (fiscal 2015) to $6.02 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 10 consecutive fiscal years. Zoetis Inc. ranks 4th of 78 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.02 | 10.05% |
| FY2024 | $5.47 | 7.89% |
| FY2023 | $5.07 | 12.92% |
| FY2022 | $4.49 | 5.15% |
| FY2021 | $4.27 | 24.85% |
| FY2020 | $3.42 | 9.97% |
| FY2019 | $3.11 | 6.14% |
| FY2018 | $2.93 | 67.43% |
| FY2017 | $1.75 | 6.06% |
| FY2016 | $1.65 | 142.65% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $1.65 | 16.20% |
| Mar 2026 | $1.42 | 3.65% |
| Dec 2025 | $1.37 | (15.95%) |
| Sep 2025 | $1.63 | 1.24% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation compare | $27.95 |
| NBIX Neurocrine Biosciences, Inc. compare | $6.82 |
| ZTS Zoetis Inc. | $6.07 |
| TAK Takeda Pharmaceutical Co. compare | $0.66 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $0.60 |
| HLN Haleon PLC Sponsored ADR compare | $0.45 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.40 |
| VTRS Viatris Inc. compare | −$0.36 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement